期刊文献+

cyclin D2、Bcl-2在弥漫大B细胞淋巴瘤中的表达意义

Expression significance of cyclin D2 and Bcl-2 in diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的研究细胞周期蛋白D2(cyclin D2)、B淋巴细胞瘤-2基因(Bcl-2)在弥漫大B细胞淋巴瘤(DLBCL)中的表达意义。方法采用回顾性分析,观察对象为2017年3月至2022年3月入东莞市人民医院就诊的80例DLBCL患者与20例淋巴组织反应性增生(RLH)患者,分别设定为研究组与对照组,两组患者均经术后病理检查确诊,术前未行任何治疗。选取免疫组织化学法测定两组cyclin D2、Bcl-2蛋白表达情况,对cyclin D2、Bcl-2表达之间的相互关系及与DLBCL患者病理特征相关性进行分析。结果研究组cyclin D2蛋白阳性率、Bcl-2蛋白阳性率分别为33.75%(27/80)、62.50%(50/80),对照组cyclin D2蛋白阳性率、Bcl-2蛋白阳性率分别为5.00%(1/20)、10.00%(2/20);研究组cyclin D2蛋白阳性率、Bcl-2蛋白阳性率较对照组更高,差异均有统计学意义(P<0.05)。cyclin D2蛋白表达、Bcl-2蛋白表达与DLBCL患者的免疫分型、Ann Arbor分期有明显相关性(P<0.05),与组织类型、肿瘤部位、性别及年龄无明显相关性(P>0.05)。DLBCL中cyclin D2与Bcl-2的表达呈正相关(r=1.000,P<0.05)。结论cyclin D2、Bcl-2在DLBCL中呈高表达,可能参与了DLBCL的发生及发展,两者具有协同作用,可辅助评价生物恶性程度。 Objective To investigate the expression significance of cyclin D2(cyclin D2)and B lymphoblastoma-2(Bcl-2)gene in diffuse large B cell lymphoma(DLBCL).Methods By retrospective analysis,80 patients with DLBCL and 20 patients with lymphoid tissue reactive hyperplasia(RLH)admitted to Dongguan People’s Hospital from March 2017 to March 2022 were divided into the study group and the control group,respectively.All patients in the two groups were confirmed by postoperative pathological examination,and did not receive any treatment before surgery.The expression of cyclin D2 and Bcl-2 protein in the two groups was determined by immunohistochemistry,and the correlation between cyclin D2 and Bcl-2 expression and pathological characteristics of DLBCL patients was analyzed.Results The positive rates of cyclin D2 protein and Bcl-2 protein in the study group were 33.75%(27/80)and 62.50%(50/80),respectively.The positive rates of cyclin D2 protein and Bcl-2 protein in the control group were 5.00%(1/20)and 10.00%(2/20),respectively.The positive rates of cyclin D2 protein and Bcl-2 protein in the study group were higher than those in the control group,and the differences were significant(P<0.05).The expression of cyclin D2 protein and Bcl-2 protein were significantly correlated with the immunotyping and Ann Arbor stage of DLBCL patients(P<0.05),but not with tissue type,tumor site,gender and age(P>0.05).The expression of cyclin D2 was positively correlated with Bcl-2 in DLBCL(r=1.000,P<0.05).Conclusion Cyclin D2 and Bcl-2 are highly expressed in DLBCL,which may be involved in the occurrence and development of DLBCL.They have synergistic effects and can assist in the evaluation of biological malignancy.
作者 胡晓婧 姚灼新 姜义荣 姚淑仪 HU Xiao-jing;YAO Zhuo-xin;JIANG Yi-rong(Department of Hematology and Lymphoma,Dongguan People's Hospital,Dongguan Guangdong 523000,China)
出处 《临床和实验医学杂志》 2023年第2期137-140,共4页 Journal of Clinical and Experimental Medicine
基金 广东省医疗卫生科技计划项目(编号:2020Y0258) 东莞市科学技术发展项目(编号:202050715001214)。
关键词 弥漫大B细胞淋巴瘤 细胞周期蛋白D2 B淋巴细胞瘤-2基因 淋巴组织反应性增生 相关性 Diffuse large B-cell lymphoma Cyclin D2 B lymphoblastoma-2 gene Reactive proliferation of lymphoid tissue Correlation
  • 相关文献

参考文献10

二级参考文献78

  • 1吕丽,唐颖,张丽,王莉芬,王乃玉,冯小海.bcl-6、bcl-2、ki-67蛋白表达与弥漫性大B细胞淋巴瘤临床特征及预后相关因素分析[J].大连医科大学学报,2009,31(1):14-17. 被引量:5
  • 2Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 3Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 4Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 5Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 6Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 7Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 8Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 9Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 10Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.

共引文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部